AlzeCure Pharma
STOCKHOLM, SE / ACCESSWIRE / September 22, 2021 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the company is participating at the Naventus Life Science Summit at Grand Hotel in Stockholm on September 29 at 09:25 CEST, where CEO Martin Jönsson will present the company's latest developments.
The event is organized by Naventus Corporate Finance together with Setterwalls, Deloitte, FNCA, Nordnet and Nasdaq.
The presentation will be held in English and live streamed via https://events.naventus.com/ . The presentation will also be available after on AlzeCure's website https://www.alzecurepharma.se/en/presentations-and-interviews/ .
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se , is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se .
Attachments
AlzeCure presents at Naventus Life Science Summit on September 29
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
https://www.accesswire.com/665112/AlzeCure-Presents-at-Naventus-Life-Science-Summit-on-September-29
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Clean Air Metals Announces Appointment of John Mason as Director15.9.2025 13:00:00 CEST | Press release
THUNDER BAY, ON / ACCESS Newswire / September 15, 2025 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSX.V:AIR)(FRA:CKU)(OTCQB: CLRMF) is pleased to announce the appointment of John Mason, D.Sc., P.Geo., as Director of the Company effective immediately. John Mason is a professional geoscientist with 49 years of experience in mineral exploration and mining in Northern Ontario. Mr. Mason's work experience includes management positions with the Ontario Ministry of Northern Development and Mines (NDMNRF) and Thunder Bay Community Economic Development Commission, before starting John Mason and Associates. John Mason has worked with all mines and major exploration projects in Northwestern Ontario, specific to supply and service, workforce, energy, and transportation access needs. John has worked with many of the indigenous communities, MNO and municipalities to maximize economic development opportunities related to exploration and mining and balance environmental/ESG require
Honoring Innovation, Excellence, and Leadership at the 2025 APEX/IFSA Awards: APEX Honored Aviation's Industry Trailblazers and Visionaries12.9.2025 08:00:00 CEST | Press release
WASHINGTON, D.C. / ACCESS Newswire / September 12, 2025 / Airlines and suppliers were celebrated for their meaningful advancements in passenger experience at the prestigious APEX/IFSA Awards Ceremony in Long Beach, California. Hosted by the APEX (Airline Passenger Experience Association) and the IFSA (International Flight Services Association) during the APEX/IFSA Global EXPO, the ceremony is regarded as the industry's premier awards event, recognizing innovation, dedication, and leadership that set new standards for excellence across the skies.APEX IFSA "What sets the APEX/IFSA Awards apart comes from how our awards program moves beyond recognition; it actively drives excellence across our entire industry," APEX/IFSA Group CEO Dr. Joe Leader stated. "Unlike other award platforms, these honors reflect both the voices of millions of global passengers and the rigorous assessments of independent experts. This powerful combination establishes the APEX/IFSA Awards as the most trusted and im
Among Migrating Nurses, Survey Shows High Satisfaction Rates for Those Who Use a Certified Ethical Recruiter11.9.2025 21:30:00 CEST | Press release
PHILADELPHIA, PA / ACCESS Newswire / September 11, 2025 / In a new survey, foreign-educated nurses and other healthcare professionals who migrate to work in the United States continue to give high marks to recruitment firms that are certified by the Alliance for Ethical International Recruitment Practices.TruMerit Ethical International Recruitment Report How certification helps safeguard the rights of foreign-educated health professionals. The Alliance, a division of TruMerit (formerly CGFNS International), in 2024 surveyed more than 8,000 foreign-educated health professionals who had used one of its 19 Certified Ethical Recruiters (CERs). Ninety percent of respondents indicated they had an overall positive experience with their recruiter, with 55% reporting it was very positive. As the survey report shows, the high satisfaction rate essentially held steady from 2023 despite persisting delays and increased costs in the U.S. immigration process. In an earlier TruMerit/CGFNS survey of it
Raven Resources Reports Strong First-Year Results Following Grove Electric Acquisition11.9.2025 15:00:00 CEST | Press release
GROVE, OKLAHOMA / ACCESS Newswire / September 11, 2025 / Raven Resources today announced robust first-year financial results following its acquisition of Grove Electric, a leading electrical contracting and services company based in Grove, Oklahoma. For the fiscal year ending August 31, 2025, Grove Electric achieved a 30% increase in revenues compared to the prior year. The September 2024 acquisition was a strategic move to expand Raven Resources' portfolio of service-oriented businesses in fast-growing regional markets. The strong results highlight both the successful integration of Grove Electric and the sustained demand for high-quality electrical contracting services across Northeast Oklahoma. "We are extremely pleased with Grove Electric's first year under Raven Resources," said Paul Scribner, CEO of Raven Resources. "The growth we've seen is a testament to the dedication of Grove Electric's team and the company's reputation for reliable, professional service. This performance rei
Richmond Terrace Capital Secures €900 Million from European Pension Leaders11.9.2025 12:30:00 CEST | Press release
CITY OF LONDON, GB / ACCESS Newswire / September 11, 2025 / Richmond Terrace Capital, a leading London-based investment management company, is pleased to announce that a consortium of leading European pension funds has awarded the firm new discretionary mandates totaling approximately €900 million, with an additional €1.5 billion in commitments scheduled for early 2026. Through these mandates, Richmond Terrace Capital will provide end-to-end portfolio management and strategic investment guidance, designed to deliver consistent value in line with each client's investment objectives. Record Momentum Powered by Strategic Growth This landmark development caps one of Richmond Terrace Capital's strongest years to date, driven by the exceptional performance of its flagship funds and private equity platforms. Investment success has been particularly evident in transformative sectors such as Commercial Space Ventures, Advanced Connectivity Infrastructure, and Artificial Intelligence application
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom